X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adamantane - analogs & derivatives (643) 643
index medicus (636) 636
humans (582) 582
diabetes mellitus, type 2 - drug therapy (392) 392
male (383) 383
adamantane - therapeutic use (344) 344
female (317) 317
adamantane - adverse effects (296) 296
middle aged (260) 260
type 2 diabetes (241) 241
hypoglycemic agents - therapeutic use (226) 226
dipeptidyl-peptidase iv inhibitors - therapeutic use (222) 222
aged (196) 196
endocrinology & metabolism (194) 194
pyrrolidines - therapeutic use (186) 186
adamantane - administration & dosage (184) 184
nitriles - therapeutic use (183) 183
treatment outcome (181) 181
adult (177) 177
dipeptidyl-peptidase iv inhibitors - adverse effects (175) 175
animals (174) 174
hypoglycemic agents - adverse effects (174) 174
vildagliptin (172) 172
adamantane - pharmacology (156) 156
pharmacology & pharmacy (154) 154
diabetes mellitus, type 2 - blood (150) 150
pyrrolidines - adverse effects (147) 147
nitriles - adverse effects (144) 144
diabetes (139) 139
drug therapy, combination (139) 139
metformin (132) 132
double-blind method (128) 128
dipeptides - adverse effects (124) 124
dipeptides - therapeutic use (123) 123
hypoglycemic agents - administration & dosage (109) 109
glycated hemoglobin a - metabolism (107) 107
blood glucose - metabolism (105) 105
saxagliptin (104) 104
blood glucose - drug effects (97) 97
glucagon-like peptide-1 (95) 95
improves glycemic control (95) 95
double-blind (94) 94
glucose (93) 93
drug therapy (92) 92
metformin - therapeutic use (88) 88
care and treatment (87) 87
dipeptidyl-peptidase iv inhibitors - administration & dosage (87) 87
efficacy (86) 86
pyrrolidines - administration & dosage (84) 84
nitriles - administration & dosage (83) 83
beta-cell function (82) 82
hypoglycemic agents (82) 82
glycemic control (79) 79
rats (75) 75
dipeptidyl peptidase-4 inhibitor (74) 74
sitagliptin (74) 74
adamantane - pharmacokinetics (72) 72
medicine, general & internal (72) 72
risk factors (72) 72
dipeptidyl-peptidase iv inhibitors - pharmacology (71) 71
analysis (70) 70
drug-naive patients (70) 70
insulin (70) 70
monotherapy (70) 70
safety (69) 69
type 2 diabetes mellitus (69) 69
diabetes therapy (68) 68
sitagliptin phosphate (67) 67
dosage and administration (66) 66
metformin - administration & dosage (66) 66
clinical trials (65) 65
dose-response relationship, drug (64) 64
hypoglycemia - chemically induced (64) 64
metformin - adverse effects (63) 63
research (63) 63
diabetes mellitus, type 2 - complications (62) 62
dpp-4 inhibitor (62) 62
hypoglycemia (60) 60
internal medicine (60) 60
mellitus (60) 60
pyrrolidines - pharmacology (60) 60
nitriles - pharmacology (59) 59
therapy (59) 59
mice (58) 58
abridged index medicus (57) 57
dipeptides - administration & dosage (57) 57
young adult (57) 57
adolescent (55) 55
administration, oral (52) 52
pyrazines - therapeutic use (52) 52
time factors (52) 52
triazoles - therapeutic use (52) 52
medicine & public health (46) 46
medicine, research & experimental (46) 46
hypoglycemic agents - pharmacology (45) 45
type-2 diabetes-mellitus (45) 45
diabetes mellitus (44) 44
glycosylated hemoglobin (44) 44
pharmacokinetics (44) 44
dextrose (43) 43
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (658) 658
Russian (16) 16
German (5) 5
Japanese (4) 4
Czech (3) 3
French (3) 3
Spanish (2) 2
Dutch (1) 1
Hungarian (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1317 - 1326
Saxagliptin, a new oral antihyperglycemic drug in the DPP-4 inhibitor class, had no effect on the risk of cardiovascular events in patients with type 2... 
ALL-CAUSE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | EVENTS | GLUCOSE CONTROL | MICROALBUMINURIA | DISEASE | CLINICAL-USE | PREVENTION | RISK | DEATH | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Adamantane - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Hypoglycemia - chemically induced | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Dipeptides - therapeutic use | Double-Blind Method | Pancreatitis - epidemiology | Dipeptides - adverse effects | Kaplan-Meier Estimate | Pancreatitis - chemically induced | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy | Heart diseases | Risk factors | Saxagliptin | Myocardial infarction | Cerebral infarction | Heart attacks | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Patients | Heart rate | Ischemia | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Diabetes Care, ISSN 0149-5992, 11/2015, Volume 38, Issue 11, pp. 2009 - 2017
OBJECTIVE To compare the efficacy and safety of treatment with dapagliflozin versus that with placebo add-on to saxagliptin plus metformin in patients whose... 
BODY-WEIGHT | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | SULFONYLUREA | PIOGLITAZONE | EFFICACY | SAFETY | CLINICAL-TRIALS | ENDOCRINOLOGY & METABOLISM | 24-WEEK | MELLITUS | INADEQUATE GLYCEMIC CONTROL | Hypoglycemia - epidemiology | Metformin - therapeutic use | Benzhydryl Compounds - administration & dosage | Humans | Middle Aged | Male | Metformin - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - chemically induced | Adamantane - therapeutic use | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Hypoglycemia - chemically induced | Glucosides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Blood Glucose - drug effects | Dipeptides - administration & dosage | Urinary Tract Infections - epidemiology | Drug Therapy, Combination - methods | Glucosides - administration & dosage | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Treatment outcome | Usage | Safety and security measures | Dapagliflozin | Analysis | Clinical trials | Dosage and administration | Metformin | Saxagliptin | Prescription drugs | Diabetes | Comparative analysis | Index Medicus
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 05/2004, Volume 89, Issue 5, pp. 2078 - 2084
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 2009, Volume 11, Issue 2, pp. 157 - 166
To examine the efficacy and safety of vildagliptin vs. glimepiride as add-on therapy to metformin in patients with type 2 diabetes mellitus in a 52-week... 
Glimepiride | Vildagliptin | Type 2 diabetes mellitus | Hypoglycaemia | DPP-4 inhibitor | GLUCOSE CONTROL | hypoglycaemia | glimepiride | DRUG-NAIVE PATIENTS | ISLET FUNCTION | PEPTIDASE-IV INHIBITOR | PIOGLITAZONE | THERAPY | vildagliptin | IMPROVES GLYCEMIC CONTROL | TOLERABILITY | ENDOCRINOLOGY & METABOLISM | type 2 diabetes mellitus | DOUBLE-BLIND | CELL-FUNCTION | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Body Weight - drug effects | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Male | Sulfonylurea Compounds - adverse effects | Metformin - adverse effects | Nitriles - administration & dosage | Diabetes Mellitus, Type 2 - blood | Hypoglycemic Agents - administration & dosage | Time Factors | Female | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Adamantane - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Type 2 diabetes | Complications and side effects | Care and treatment | Analysis | Glycosylated hemoglobin | Glucose | Dextrose | Diabetes therapy | Index Medicus | Clinical Medicine | Endokrinologi och diabetes | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Endocrinology and Diabetes
Journal Article
Diabetes/Metabolism Research and Reviews, ISSN 1520-7552, 2010, Volume 26, Issue 7, pp. 540 - 549
Journal Article
Diabetes Care, ISSN 0149-5992, 09/2009, Volume 32, Issue 9, pp. 1649 - 1655
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone Ralph A.... 
ORAL GLUCOSE-TOLERANCE | POTENT | MONOTHERAPY | GLUCAGON-LIKE PEPTIDE-1 | GLYCEMIC DURABILITY | INSULIN-RESISTANCE | ENDOCRINOLOGY & METABOLISM | SECRETION | MELLITUS | INHIBITOR | Metformin - therapeutic use | Humans | Middle Aged | Male | Metformin - adverse effects | Young Adult | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Placebos | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Adamantane - pharmacology | Dipeptides - therapeutic use | Double-Blind Method | Dipeptides - adverse effects | Dipeptides - pharmacology | Metformin - pharmacology | Treatment Outcome | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Dipeptides - administration & dosage | Adolescent | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Diabetics | Medical research | Care and treatment | Medicine, Experimental | Glucose | Pharmaceutical industry | Dextrose | Diabetes therapy | Heart failure | Physical examinations | Drug abuse | Substance abuse treatment | Research methodology | Patient care planning | Diabetes | Safety | Drug therapy | Hypoglycemia | Apoptosis | Index Medicus | Original Research
Journal Article